Furthermore, the anti-tumor efficacy of CD28-PD1 CRS expressed in TRuCT cells was validated in mice bearing MSLN-positive tumors, and this strategy is currently being investigated in a phase I/II clinical trial (NCT05451849) (Table 1). Here, PDCD1 is linked to neoplasm.